Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies

DOI

10.2991/chi.d.190219.001How to use a DOI?

Keywords

CAR-T cells; Acute lymphoblastic leukemia; CD19; Non-Hodgkin's lymphoma

Abstract

Application of immunotherapeutic modalities changed paradigms in the treatment of hematologic malignancies, with regards to drug manufacturing, treatment protocols, short- and long-term toxicities. FDA-approved therapies, including blinatumomab, tisagenlecleucel, and axicabtagene ciloleucel, target T cells to attack healthy and malignant cells expressing CD19, leading to high response rates in previously heavily treated patients, and to durable remissions in the absence of further therapies. Nevertheless, despite paucity of long-term data, some patients are resistant to these agents, and many relapse. This review will discuss the mechanisms of failure of these immune-based therapies, and offer guidelines to the practicing physician.

Copyright

© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - Elad Jacoby
PY  - 2019
DA  - 2019/06/11
TI  - Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
JO  - Clinical Hematology International
SP  - 79
EP  - 84
VL  - 1
IS  - 2
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190219.001
DO  - 10.2991/chi.d.190219.001
ID  - Jacoby2019
ER  -